Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does the dose of methotrexate influence the rate of relapse in patients with Wegener's granulomatosis?

Nature Clinical Practice Rheumatology volume 4, pages 12–13 (2008)Cite this article

boxed-textMetzler et al. (2007) Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 46: 1087–1091

In patients with Wegener's granulomatosis, treatment with methotrexate should be started at 15 mg/week and increased to 20–25 mg/week within 2–4 weeks in the absence of cytopenias or other dose-limiting toxicities

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Sneller MC et al. (1995) An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 38: 608–613

    Article  CAS  Google Scholar 

  2. Langford CA et al. (1999) A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 42: 2666–2673

    Article  CAS  Google Scholar 

  3. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group (2005) Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352: 351–361

  4. De Groot K et al. (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52: 2461–2469

    Article  CAS  Google Scholar 

  5. Metzler C et al. (2004) Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford) 43: 315–320

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Jasmine Farsarakis, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Department of Rheumatic and Immunologic Diseases, ES Molloy is a Fellow and CA Langford is the Director of the Center for Vasculitis Care and Research, Cleveland Clinic, Ohio, USA.,

    Eamonn S Molloy & Carol A Langford

Authors
  1. Eamonn S Molloy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carol A Langford
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carol A Langford.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Molloy, E., Langford, C. Does the dose of methotrexate influence the rate of relapse in patients with Wegener's granulomatosis?. Nat Rev Rheumatol 4, 12–13 (2008). https://doi.org/10.1038/ncprheum0675

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncprheum0675

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing